Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › bimekizumab

bimekizumab

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of bimekizumab

27 trials tracked of bimekizumab: 15 in phase 3 or 4 and 13 with published results. The most-cited published study has 105 citations.

27Trials tracked
15Phase 3 & 4
0Recruiting
13With published results
Phase distribution
Phase 3 15 Phase 2 11 Phase 1 1
  1. Phase 3 A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis Completed · 105 cited
  2. Phase 3 A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis Completed · 105 cited
  3. Phase 3 A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Completed · 57 cited
  4. Phase 3 A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Completed · 57 cited
  5. Phase 3 A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Completed · 57 cited
  6. Phase 3 A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Completed · 57 cited
Show 21 more trials
  1. Phase 3 A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis Completed · 43 cited
  2. Phase 3 A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Completed · 39 cited
  3. Phase 3 A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis Completed · 9 cited
  4. Phase 3 A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa Completed · 6 cited
  5. Phase 3 A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO) Completed · 5 cited
  6. Phase 3 A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis Completed · 5 cited
  7. Phase 3 A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa Completed · 5 cited
  8. Phase 3 A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis Completed
  9. Phase 3 A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis Completed
  10. Phase 2 A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis Completed
  11. Phase 2 A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis Completed
  12. Phase 2 A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa. Completed
  13. Phase 2 A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis Completed
  14. Phase 2 A Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis Completed
  15. Phase 2 A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis Completed
  16. Phase 2 A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis Completed
  17. Phase 2 A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis Completed
  18. Phase 2 A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis Completed
  19. Phase 2 Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis Completed
  20. Phase 2 A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis Completed
  21. Phase 1 A Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants Completed

Showing the 27 most-cited and recently-updated of 27 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Bimekizumab maintains complete skin clearance in 73% of psoriasis patients at 4 years
Dermatology RCT
Bimekizumab maintains complete skin clearance in 73% of psoriasis patients at 4 years Can psoriasis treatment keep skin clear for years? New data suggests it might
A pooled analysis of phase 3 trials and open-label extension in 503 psoriasis patients found 73.0% of those achieving complete clearance at …
After four years on bimekizumab, about 73% of patients with psoriasis kept their skin completely clear, suggesting the treatment may help re…
Apr 6, 2026
Phase 2a study of bimekizumab in chronic plaque psoriasis reports pharmacokinetics and PASI change at Week 28
Dermatology Phase II
Phase 2a study of bimekizumab in chronic plaque psoriasis reports pharmacokinetics and PASI change at Week 28 Could a new psoriasis treatment work better by targeting two inflammation sources at once?
A Phase 2a, multicenter, randomized, subject- and investigator-blind study investigated the pharmacokinetics, pharmacodynamics, and safety o…
A new psoriasis drug targets two inflammation sources to see if it works better for thick, scaly skin patches in adults.
CT.gov Mar 30, 2026
Phase 3 trial compares bimekizumab to placebo and ustekinumab for moderate to severe plaque psoriasis
Rheumatology Phase III
Phase 3 trial compares bimekizumab to placebo and ustekinumab for moderate to severe plaque psoriasis Can a new psoriasis drug outperform an established treatment?
A phase 3 randomized controlled trial enrolled 567 adults with moderate to severe chronic plaque psoriasis to compare bimekizumab against pl…
A new psoriasis drug called bimekizumab is being tested against existing treatments in a major trial involving 567 adults to see if it helps…
CT.gov Mar 30, 2026
Phase 3 trial of bimekizumab versus placebo in 435 adults with moderate to severe plaque psoriasis
Dermatology Phase III
Phase 3 trial of bimekizumab versus placebo in 435 adults with moderate to severe plaque psoriasis Can a new drug help people with moderate to severe plaque psoriasis?
A phase 3 randomized controlled trial evaluated bimekizumab versus placebo in 435 adults with moderate to severe chronic plaque psoriasis.
A new drug tested in a large study aims to help clear skin for people with moderate to severe plaque psoriasis.
CT.gov Mar 30, 2026